BTT-3033

Overview

BTT-3033 is an orally active conformation-selective inhibitor of α2β1 ( EC50 : 130 nM) by binding to the α2I domain. BTT-3033 inhibits platelet binding to collagen I and cell proliferation, and induces cell apoptosis . BTT-3033 can be used in the research of prostate cancer , inflammation and cardiovascular disease .

Application

Products | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Prostate Cancer | Products > Disease Areas > Urogenital Cancer | Products > Disease Areas > Digestive System Inflammation | Products > Disease Areas > Cardiovascular Disease | Products > Disease Areas > Cancer | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Urogenital Disease | Products > Signaling Pathways > Cytoskeleton | Products > Signaling Pathways > Apoptosis | Products > Research Areas > Inflammation/Immunology | Products > Research Areas > Cardiovascular Disease | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Integrin | Products > Signaling Pathways > Apoptosis

Product Information

• Catalog No.: HY-110112
• CAS No.: 1259028-99-3
• Molecular Formula: C23H20FN5O3S
• Molecular Weight: 465.50
• Purity: 96.57%
• Storage: Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Availability: In-stock

Source

Original product source